NANOVIRICIDES, INC.
NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biopharmaceutical company developing a novel class of antiviral drugs based on its proprietary nanoviricide platform technology. The company's website is located at http://www.Nanoviricides.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NANOVIRICIDES, INC. does
In the company’s own words
NanoViricides, Inc. (NYSE American: NNVC) is a clinical-stage biopharmaceutical company developing a novel class of antiviral drugs based on its proprietary nanoviricide platform technology. The company's website is located at http://www.Nanoviricides.com.
The company is focused on creating host-mimetic, direct-acting nanomachine drugs designed to dismantle targeted virus particles without requiring assistance from the human immune system. NanoViricides' platform technology addresses a fundamental challenge in antiviral development: the tendency of viruses to rapidly evolve and escape traditional therapeutic approaches such as vaccines, antibodies, and small chemical drugs. The company's nanoviricides are designed to mimic host-cell attachment and cognate receptors that viruses require for infection, theoretically preventing viral escape through mutation since viruses must continue using the same cellular landing sites despite evolutionary changes.
The company's most advanced drug candidate is NV-387, a broad-spectrum antiviral that has completed Phase Ia/Ib human clinical safety and tolerability trials and is positioned to enter Phase II efficacy studies. NV-387 demonstrated strong activity in animal models against multiple virus families including coronavirus, respiratory syncytial virus, influenza, orthopoxviruses, and measles. The drug has been formulated in multiple delivery formats including oral syrup, oral gummies, injectable, intravenous infusion, and inhalation solutions.
NanoViricides maintains fully integrated development and manufacturing capabilities at its facility in Shelton, Connecticut, supporting the entire drug development process from discovery through cGMP-compatible manufacturing and analytical testing. The company holds exclusive, worldwide licenses from TheraCour Pharma for treatment of numerous viral diseases including HIV/AIDS, hepatitis B and C, herpes simplex viruses, influenza, dengue, Ebola, and varicella zoster virus.
The company's pipeline includes NV-HHV-1 for herpesvirus infections formulated as a skin cream for shingles treatment, and NV-HIV-1 targeting HIV infection. Additional drug candidates are in preclinical development for dengue, Ebola, and other viral indications. NanoViricides has no approved products, customers, or revenues to date and may never achieve profitable operations.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SHELTON, CT
- Fiscal year end
- June
- CIK
- 1379006
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NANOVIRICIDES, INC. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NANOVIRICIDES, INC.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NANOVIRICIDES, INC. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NANOVIRICIDES, INC.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NANOVIRICIDES, INC.'s last four quarterly filings that the numbers alone won't show?”